We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 26, 2022

Association Between SGLT2 Inhibitor Treatment and DKA and Mortality in People With Type 2 Diabetes Hospitalised for COVID-19

Diabetes Care

 

Additional Info

Diabetes Care
Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19
Diabetes Care 2022 Sep 08;[EPub Ahead of Print], K Khunti, Y Ruan, J Davies, BCT Field, S Harris, M Kosiborod, D Nagi, P Narendran, D Patel, REJ Ryder, KA Várnai, SH Wild, EG Wilmot, R Rea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading